What do systematic reviews say?

Intervention not reported

• Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 224 participants
  Low

Radiotherapy (morning) vs Afternoon radiotherapy

• Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
  Bjarnason 2009: no statistically significant difference in quality of life scores (data not reported). Morning radiotherapy was associated with significantly less weight loss after 5 months.
  1 study · 216 participants
  GRADE not reported

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sorafenib vs sunitinib (targeted agent versus targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Honey vs standard dressing

The review found no eligible studies for this question.

• Honey as a topical treatment for wounds 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical antifungal vs placebo/no treatment

Topical antifungal may leads to lower heath‐related quality of life (HRQL) compared with placebo/no treatment (low certainty).

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone

• Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 382 participants
  Low

Minimally invasive surgery vs Standard therapy alone (radiotherapy or chemoradiotherapy)

The review found no eligible studies for this question.

• Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small‐volume primary oropharyngeal carcinoma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Sorafenib vs pazopanib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Low

Pazopanib vs sunitinib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 467 participants
  Low

Laser therapy vs no laser therapy

The review found no eligible studies for this question.

• Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found